ArticlePharmacoEconomics2024

Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Dong-Won Kang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.